Wells Fargo & Company Autolus Therapeutics PLC Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Wells Fargo & Company holds 266,315 shares of AUTL stock, worth $551,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares

266,315

Previous 385,873 30.98%

Holding current value

$551,272

Previous $1.4 Million 55.36%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 12, 2025	SELL	$2.18 - $4.8 $260,636 - $573,878	-119,558 Reduced 30.98%	266,315 $625,000
Q3 2024 Nov 13, 2024	BUY	$3.38 - $4.69 $18,816 - $26,109	5,567 Added 1.46%	385,873 $1.4 Million
Q2 2024 Aug 13, 2024	BUY	$3.33 - $5.68 $11,768 - $20,073	3,534 Added 0.94%	380,306 $1.32 Million
Q1 2024 May 10, 2024	SELL	$5.39 - $7.29 $165,354 - $223,642	-30,678 Reduced 7.53%	376,772 $2.4 Million
Q4 2023 Feb 09, 2024	SELL	$2.13 - $6.63 $319,659 - $994,997	-150,075 Reduced 26.92%	407,450 $2.62 Million
Q3 2023 Nov 13, 2023	BUY	$2.32 - $3.36 $88,352 - $127,958	38,083 Added 7.33%	557,525 $1.3 Million
Q2 2023 Aug 15, 2023	BUY	$1.64 - $3.21 $52,599 - $102,954	32,073 Added 6.58%	519,442 $1.24 Million
Q1 2023 May 12, 2023	BUY	$1.75 - $2.25 $195,489 - $251,343	111,708 Added 29.74%	487,369 $896,000
Q4 2022 Feb 13, 2023	SELL	$1.74 - $3.27 $24,669 - $46,362	-14,178 Reduced 3.64%	375,661 $713,000
Q3 2022 Nov 14, 2022	BUY	$2.04 - $3.76 $52,803 - $97,323	25,884 Added 7.11%	389,839 $834,000
Q2 2022 Aug 12, 2022	BUY	$2.04 - $4.68 $253,612 - $581,817	124,320 Added 51.88%	363,955 $1.03 Million
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $142,426 - $220,922	40,462 Added 20.32%	239,635 $1 Million
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $276,710 - $379,799	-54,257 Reduced 21.41%	199,173 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $587,466 - $813,839	110,426 Added 77.22%	253,430 $1.66 Million
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $348,309 - $580,029	72,868 Added 103.9%	143,004 $950,000
Q1 2021 May 13, 2021	BUY	$5.49 - $9.36 $238,051 - $405,858	43,361 Added 161.95%	70,136 $401,000
Q4 2020 Feb 09, 2021	BUY	$8.13 - $12.79 $83,673 - $131,634	10,292 Added 62.44%	26,775 $239,000
Q3 2020 Nov 05, 2020	BUY	$11.64 - $16.3 $46,641 - $65,314	4,007 Added 32.12%	16,483 $191,000
Q2 2020 Aug 13, 2020	SELL	$5.38 - $16.14 $13,154 - $39,462	-2,445 Reduced 16.39%	12,476 $200,000
Q1 2020 May 14, 2020	BUY	$4.2 - $13.0 $62,668 - $193,973	14,921 New	14,921 $89,000

Others Institutions Holding AUTL

# of Institutions

112

Shares Held

156M

Call Options Held

Put Options Held

116K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $188M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Autolus Therapeutics PLC Transaction History